Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + pirfenidone + chemotherapy in advanced triple-negative breast cancer
ChiCTR2500109774Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in breast cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500109774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109774.